$50.50
▲ +0.2% Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron
Overview
52-week range
$16
$95
44% of range
Avg surprise (last 3)
-10.3%
Avg reaction (last 2)
-1.7%
50% positive
Latest IV / EM
88%
EM ±20.1% · $50 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.35 | $-0.39 | +10.3% | -29.6% | -4.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.37 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.36 | $-0.28 | -28.6% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.27 | $-0.24 | -12.5% | — | +0.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.20 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.18 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.21 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.20 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.39 | -$0.36 | -8.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-89M | — | $-74M | $-70M | $-56M | — | $-46M | $-33M |
| Net income | $-76M | — | $-66M | $-62M | $-47M | — | $-34M | $-26M |
| EPS (diluted) | $-0.35 | — | $-0.37 | — | $-0.27 | — | $-0.20 | $-0.18 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $316M | $800M | $103M | $147M | $152M | $170M | $172M | $382M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.49B | $1.57B | $814M | $799M | $850M | $891M | $924M | $938M |
| Total assets | $1.51B | $1.58B | $832M | $816M | $867M | $903M | $933M | $947M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $61M | $68M | $62M | $44M | $42M | $38M | $36M | $26M |
| Total equity | $1.45B | $1.52B | $770M | $772M | $825M | $865M | $897M | $921M |